Advantages and clinical applications of natural killer cells in cancer immunotherapy

被引:83
作者
Ames, Erik [1 ]
Murphy, William J. [1 ]
机构
[1] Univ Calif Davis, Sch Med, Dept Dermatol, Sacramento, CA 95817 USA
基金
美国国家卫生研究院;
关键词
NK cells; HSCT; Adoptive transfer; Cytokines; CITIM; 2013; MARROW ALLOGRAFT-REJECTION; CLASS-I MOLECULES; NK CELLS; TUMOR-CELLS; RECOMBINANT INTERLEUKIN-2; PROTEASOME INHIBITION; EFFECTOR-CELLS; LEUKEMIA-CELLS; LINE NK-92; IFN-GAMMA;
D O I
10.1007/s00262-013-1469-8
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The past decade has witnessed a burgeoning of research and further insight into the biology and clinical applications of natural killer (NK) cells. Once thought to be simple innate cells important only as cytotoxic effector cells, our understanding of NK cells has grown to include memory-like responses, the guidance of adaptive responses, tissue repair, and a delicate paradigm for how NK cells become activated now termed "licensing" or "arming." Although these cells were initially discovered and named for their spontaneous ability to kill tumor cells, manipulating NK cells in therapeutic settings has proved difficult and complex in part due to our emerging understanding of their biology. Therapies involving NK cells may either activate endogenous NK cells or involve transfers of exogenous cells by hematopoietic stem cell transplantation or adoptive cell therapy. Here, we review the basic biology of NK cells, highlighting characteristics which make NK cells particularly useful in cancer therapies. We also explore current treatment strategies that have been used for cancer as well as discuss potential future directions for the field.
引用
收藏
页码:21 / 28
页数:8
相关论文
共 53 条
[1]   Sensitization of human breast cancer cells to natural killer cell-mediated cytotoxicity by proteasome inhibition [J].
Ames, E. ;
Hallett, W. H. D. ;
Murphy, W. J. .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 2009, 155 (03) :504-513
[2]   Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial [J].
Arai, S. ;
Meagher, R. ;
Swearingen, M. ;
Myint, H. ;
Rich, E. ;
Martinson, J. ;
Klingemann, H. .
CYTOTHERAPY, 2008, 10 (06) :625-632
[3]   The immunobiology of natural killer cells and bone marrow allograft rejection [J].
Barao, I ;
Murphy, WJ .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2003, 9 (12) :727-741
[4]  
BENNETT M, 1973, J IMMUNOL, V110, P510
[5]   BIOLOGY AND GENETICS OF HYBRID RESISTANCE [J].
BENNETT, M .
ADVANCES IN IMMUNOLOGY, 1987, 41 :333-445
[6]   Clinical-grade ex vivo-expanded human natural killer cells up-regulate activating receptors and death receptor ligands and have enhanced cytolytic activity against tumor cells [J].
Berg, Maria ;
Lundqvist, Andreas ;
McCoy, Philip, Jr. ;
Samsel, Leigh ;
Fan, Yong ;
Tawab, Abdul ;
Childs, Richard .
CYTOTHERAPY, 2009, 11 (03) :341-355
[7]   IL-2-based immunotherapy after autologous transplantation for lymphoma and breast cancer induces immune activation and cytokine release: a phase I/II trial [J].
Burns, LJ ;
Weisdorf, DJ ;
DeFor, TE ;
Vesole, DH ;
Repka, TL ;
Blazar, BR ;
Burger, SR ;
Panoskaltsis-Mortari, A ;
Keever-Taylor, CA ;
Zhang, MJ ;
Miller, JS .
BONE MARROW TRANSPLANTATION, 2003, 32 (02) :177-186
[8]   Establishment, Characterization, and Successful Adaptive Therapy Against Human Tumors of NKG Cell, a New Human NK Cell Line [J].
Cheng, Min ;
Ma, Juan ;
Chen, Yongyan ;
Zhang, Jianhua ;
Zhao, Weidong ;
Zhang, Jian ;
Wei, Haiming ;
Ling, Bin ;
Sun, Rui ;
Tian, Zhigang .
CELL TRANSPLANTATION, 2011, 20 (11-12) :1731-1746
[9]  
Chikamatsu K, 1999, INT J CANCER, V82, P532, DOI 10.1002/(SICI)1097-0215(19990812)82:4<532::AID-IJC11>3.3.CO
[10]  
2-7